GlassScriptPhysician profile
Kevin P Macy
NPI 1194763193
$8,033.41
in general payments reported to CMS, 2019-2025
41 companies · $2,838 in 2025
The $2,838 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.65 · 2022: $523 · 2023: $2,066 · 2024: $2,590 · 2025: $2,838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,479 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,479.38 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,530.49 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,230.07 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $777.70 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $477.65 | 2022-2025 | Evenity, Repatha, Otezla |
| Pfizer INC. | $465.01 | 2023-2025 | |
| Novo Nordisk INC | $459.84 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $256.06 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $217.74 | 2023-2025 | Xifaxan |
| Astellas Pharma US INC | $203.68 | 2024-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $189.17 | 2022-2025 | |
| Corcept Therapeutics | $180.64 | 2023-2024 | Korlym |
| Antares Pharma, INC. | $160.33 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.33 | 2023-2025 | Jardiance, Synjardy, Spiriva Respimat |
| Abbott Laboratories | $142.30 | 2022-2025 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $131.11 | 2023-2025 | Sunosi, Auvelity, Symbravo |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Macy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.